Buprenorphine intranasal - Vernalis

Drug Profile

Buprenorphine intranasal - Vernalis

Alternative Names: IX-1003; V-1003

Latest Information Update: 16 Aug 2010

Price : $50

At a glance

  • Originator Vernalis
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Pain; Postoperative pain

Most Recent Events

  • 13 Sep 2007 Reckitt Benckiser terminates its involvement in the development of buprenorphine intranasal
  • 16 Mar 2006 Data from a media release have been added to the adverse events and Pain therapeutic trials sections
  • 26 Jul 2005 Ionix Pharmaceuticals has been acquired and merged into Vernalis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top